Importantly, since the presence of IDH mutations has been shown to correlate with better OS and progression-free survival (PFS) in GBM patients, this aberration became the only molecular marker included in the updated 2016 WHO classification of astroglial brain tumors [8, 78]. The gene discussed is IDH1; the disease is glioblastoma.